The nuclear receptor, farnesoid X receptor (FXR/NR1H4), is increasingly recognized as a promising drug target for metabolic diseases, including nonalcoholic steatohepatitis (NASH). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.